12:00 AM
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

ApoCell regulatory update

FDA granted Orphan Drug designation for Enlivex's ApoCell to treat graft-versus-host disease (GvHD). An open-label, Israeli Phase I/II trial...

Read the full 72 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >